Botulinum A toxin injections into the detrusor: An effective treatment in idiopathic and neurogenic detrusor overactivity?

被引:103
作者
Kessler, TM [1 ]
Danuser, H [1 ]
Schumacher, M [1 ]
Studer, UE [1 ]
Burkhard, FC [1 ]
机构
[1] Univ Bern, Dept Urol, CH-3010 Bern, Switzerland
关键词
botulinum A toxin; idiopathic detrusor overactivity; injections into the detrusor; neurogenic detrusor overactivity;
D O I
10.1002/nau.20105
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
=Aims: To assess and compare the effect of botulinum A toxin (BTX-A) injections into the detrusor in idiopathic and neurogenic detrusor overactivity resistant to anticholinergic treatment. Patients and Methods: in a prospective study, 11 patients with idiopathic and 11 with neurogenic detrusor overactivity resistant to anticholinergic treatment were injected with 300 U of BTX-A (Botox (R)) into the detrusor. Clinical and urodynamic parameters were assessed before and after BTX-A injections. Results: In idiopathic as well as in neurogenic cletrusor overactivity, median daytime frequency decreased significantly from 11 to 4 (P = 0.004) and 12 to 5 (P = 0.001), median nocturia from 3 to 1 (P = 0.004) and 3 to 1 (P = 0.001), and median number of used pads from 5 to 0 (P = 0.001) and 5 to 0 (P = 0.002), respectively. There was a significant increase in median maximum cystometric capacity from 220 to 340 nil (11 = 0.001) and 190 to 410 ml (to instead of) (P = 0.001), median bladder compliance from 20 to 55 ml/cmH(2)O (11 0.001) and 23 to 60 ml/cmH(2)O (P = 0.004) and median post void residual from 10 to 140 nil (P = 0.002) and 30 to 240 ml (P = 0.002), respectively. Median maximum cletrusor pressure decreased significantly from 45 to 29 cmH(2)O (P = 0.002) and 40 to 24 cmH(2)O (P = 0.002), and median detrusor pressure at maximum flow rate from 30 to 14 ml/sec (P = 0.001) and 38 to 21 ml/sec (P = 0.016), respectively. Due to post void residuals > 150 ml following BTX-A injections, de novo clean intermittent self-catheterization was necessary in nine patients (four with idiopathic and five with neurogenic cletrusor overactivity) and in one patient (with idiopathic detrusor overactivity) a suprapubic catheter was placed. The effect of BTX-A injections lasted for a median time of 5 months in both idiopathic and neurogenic detrusor overactivity. There was no significant difference in idiopathic compared to neurogenic detrusor overactivity in regard to clinical and urodynamic parameters assessed before and after BTX-A injections. Conclusions: BTX-A injections into the cletrusor have a significant and comparable but temporally limited effect in idiopathic and neurogenic detrusor overactivity resistant to anticholinergic treatment. Neurourol. Urodynam. 24:231-236,2005. 0 2005 Wiley-Liss, Inc.
引用
收藏
页码:231 / 236
页数:6
相关论文
共 19 条
  • [1] Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052
  • [2] Chancellor MB, 2003, J UROLOGY, V169, P351
  • [3] Botulinum toxin and its applications in the lower urinary tract
    Harper, M
    Fowler, CJ
    Dasgupta, P
    [J]. BJU INTERNATIONAL, 2004, 93 (06) : 702 - 706
  • [4] Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents
    Kuo, HC
    [J]. UROLOGY, 2004, 63 (05) : 868 - 872
  • [5] Botulinum toxin as a new therapy option for voiding disorders: Current state of the art
    Leippold, T
    Reitz, A
    Schurch, B
    [J]. EUROPEAN UROLOGY, 2003, 44 (02) : 165 - 174
  • [6] Loch A., 2003, European Urology Supplements, V2, P172, DOI 10.1016/S1569-9056(03)80680-2
  • [7] Botulinum toxin type B for type A resistant bladder spasticity
    Pistolesi, D
    Selli, C
    Rossi, B
    Stampacchia, G
    [J]. JOURNAL OF UROLOGY, 2004, 171 (02) : 802 - 803
  • [8] Radziszewski P., 2002, European Urology Supplements, V1, P134, DOI 10.1016/S1569-9056(02)80519-X
  • [9] Use of botulinum - A toxin for the treatment of refractory overactive bladder symptoms: An initial experience
    Rapp, DE
    Lucioni, A
    Katz, EE
    O'Connor, RC
    Gerber, GS
    Bales, GT
    [J]. UROLOGY, 2004, 63 (06) : 1071 - 1075
  • [10] Botulinum toxin type B injection for management of type A resistant neurogenic detrusor overactivity - Editorial comment
    Chancellor, MB
    [J]. JOURNAL OF UROLOGY, 2004, 171 (02) : 804 - 805